https://www.marketscreener.com/quote/stock/WINDTREE-THERAPEUTICS-INC-54601701/news/Windtree-Therapeutics-Announces-First-Patient-Dosed-in-Phase-2-Study-of-Istaroxime-for-the-Acute-T-31455659/?utm_source=telegram&utm_medium=social&utm_campaign=share